Summit Therapeutics joins working group
The Antimicrobials Working Group announced that Summit Therapeutics plc is joining its coalition of companies to work on combating drug-resistant infections.
Summit is developing new mechanism antibiotics for C. difficile infection and gonorrhea, AWG said. The group now has 19 antimicrobial drug and diagnostic device development companies in the United States and Europe.
"Summit Therapeutics is committed to antibiotic innovation, and is one of several AWG member companies with locations both in the United States and abroad," said Jeffrey Stein, Ph.D., president and CEO of Cidara Therapeutics and Chairman of AWG.
"Antimicrobial resistance is one of the greatest threats to public health worldwide, and will require coordinated action by stakeholders across government, academia and industry to ensure doctors and patients have a full armamentarium of treatment options. AWG looks forward to continued collaboration at all levels to advance legislation and regulatory policies that support innovation in the treatment of infectious diseases."